Retatrutide: beyond the scale
The triple-hormone agonist is famous for ~24% weight loss — but the trial data also point to cardiometabolic and joint signals. Here's what's actually published vs. what's still pending.
Code HIGHPEPTIDES takes 15% off at checkout: $68
Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
How It Works
Retatrutide (LY3437943) activates GIP, GLP-1 and glucagon receptors.
The Phase 2 trial abstracts cited here report large weight loss but do not report lipid or blood-pressure results. Reviews of obesity medications describe lipid, blood-pressure and glycemic benefits as a class; retatrutide-specific lipid and blood-pressure data are not established here.
In type 2 diabetes, retatrutide lowered HbA1c by up to 2.02% at 24 weeks (vs ~0% placebo and outperforming dulaglutide at higher doses), with weight loss up to ~17% at 36 weeks.
Phase 3 TRIUMPH-1 has now reported both: in 574 participants with knee osteoarthritis, retatrutide 9 mg and 12 mg cut WOMAC pain scores (1–10 scale) by 1.6 and 1.8 points more than placebo, and in 243 participants with obstructive sleep apnea they cut the apnea-hypopnea index by 24.4 and 21.9 events per hour more than placebo (NEJM 2026, PMID 42814954).
Affiliate link: HighPeptides earns a commission on orders.
What the Data Shows
Key Takeaways
- In the Phase 2 obesity trial, 12 mg cut body weight 24.2% at 48 weeks; 83% of that group lost ≥15% of body weight (NEJM 2023, PMID 37366315).
- In type 2 diabetes, retatrutide lowered HbA1c up to 2.02% at 24 weeks and reduced weight ~17% at 36 weeks (Lancet 2023, PMID 37385280).
- A Phase 3 trial (TRANSCEND-T2D-1) confirmed glycemic and weight efficacy in T2D inadequately controlled on diet/exercise (Lancet 2026, PMID 42250575).
- Reviews of obesity medications describe multisystem cardiometabolic benefits — lipids, blood pressure, glycemia — that accompany the weight loss (Lancet Diabetes Endocrinol 2026, PMID 42208956).
- The registrational TRIUMPH program was designed to test knee osteoarthritis and obstructive sleep apnea (Diabetes Obes Metab 2026, PMID 41090431). Both phase 3 sleep apnea trials have now reported: in TRIUMPH-2-OSA (448 adults with type 2 diabetes), 9 mg and 12 mg cut the apnea-hypopnea index by 14.4 and 15.1 events per hour more than placebo at 80 weeks (NEJM 2026, PMID 42904878).
- A dose-dependent rise in heart rate peaked at 24 weeks and then declined (NEJM 2023, PMID 37366315).
- Retatrutide is investigational — not FDA-approved for any use as of mid-2026.
- The viral 'knee OA pain reduced 75.8%' figure is NOT from a peer-reviewed publication; the published TRIUMPH-1 knee-OA and sleep-apnea results (NEJM 2026, PMID 42814954) are point changes in pain score and apnea events per hour, not that percentage.
- Lipid and blood-pressure percentage changes for retatrutide are not reported in the trial abstracts cited here — treat specific social-media numbers with caution until you can check them against full publications.
- There is no completed long-term cardiovascular-outcomes trial for retatrutide yet.
- Whether cardiometabolic gains are independent of weight loss has not been established in these trials.
- Gastrointestinal side effects (nausea, diarrhea, vomiting) are common and dose-related.
Frequently Asked Questions
Does retatrutide lower cholesterol and blood pressure?
This page makes no specific cholesterol or blood-pressure claim for retatrutide: the Phase 2 trial abstracts cited here report weight and glycemic outcomes, not lipid or blood-pressure results. Check any lipid or blood-pressure figures against the full publications rather than social-media summaries.
How much weight do you lose on retatrutide?
In the Phase 2 obesity trial, the 12 mg dose reduced body weight by an average of 24.2% at 48 weeks, and 83% of participants on that dose lost at least 15% of their body weight (NEJM 2023).
Is retatrutide good for knee osteoarthritis?
In the Phase 3 TRIUMPH-1 trial (NEJM 2026, PMID 42814954), among 574 participants with obesity and knee osteoarthritis, retatrutide 9 mg and 12 mg reduced WOMAC knee-pain scores (1–10 scale) by 1.6 and 1.8 points more than placebo. Results are reported as point changes on that scale, not the pain-reduction percentages circulating online.
Does retatrutide help type 2 diabetes?
Yes — in a Phase 2 trial it lowered HbA1c by up to 2.02% at 24 weeks while also reducing weight, and a Phase 3 trial (TRANSCEND-T2D-1) has since confirmed glycemic and weight efficacy in people with type 2 diabetes.
Is retatrutide FDA approved?
No. As of mid-2026 retatrutide remains investigational and is in Phase 3 trials; it is not approved by the FDA for weight loss, diabetes, or any other indication.
Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify). HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The GLP-1 Owner’s Manual ($19) The GLP-1 Owner’s Manual ($19) All ebooks & guides →Educational purposes only. Not medical advice.
Retatrutide is an investigational compound and is not FDA-approved. Discuss any therapy with a qualified clinician.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.